Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614400 | 0.87 | PTGDR2 (0.40) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4983690 | 0.84 | DGAT1 (0.39) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL17645913 | 0.80 | MEN1 (0.50) | PDE2ASMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL1328840 | 0.75 | DGAT1 (0.42) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL3993190 | 0.74 | DGAT1 (0.41) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4478221 | 0.74 | KIF11 (0.39) | DGAT1SMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL31292276 | 0.74 | DGAT1 (0.41) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL17391120 | 0.74 | PTGDR2 (0.43) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL16428016 | 0.74 | PTGDR2 (0.38) | DGAT1NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL9953037 | 0.73 | PTGDR2 (0.40) | DGAT1NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | DGAT1 2612/4885NPC1 135/4885RAB9A 670/4885 |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | DGAT1 4782/4885NPC1 4265/4885RAB9A 1637/4885 |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | DGAT1 4681/4885NPC1 2887/4885RAB9A 1376/4885 |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | DGAT1 4679/4885NPC1 2895/4885RAB9A 1384/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | DGAT1 2591/4885NPC1 157/4885RAB9A 655/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | DGAT1 2591/4885NPC1 157/4885RAB9A 655/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | DGAT1 2612/4885NPC1 135/4885RAB9A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.